EP1037628A4 - METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE - Google Patents

METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE

Info

Publication number
EP1037628A4
EP1037628A4 EP98960259A EP98960259A EP1037628A4 EP 1037628 A4 EP1037628 A4 EP 1037628A4 EP 98960259 A EP98960259 A EP 98960259A EP 98960259 A EP98960259 A EP 98960259A EP 1037628 A4 EP1037628 A4 EP 1037628A4
Authority
EP
European Patent Office
Prior art keywords
tocotrienols
methods
preventing restenosis
restenosis
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98960259A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1037628A1 (en
Inventor
Ronald H Lane
Frederick H Schneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lipogenics Inc
Original Assignee
Lipogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lipogenics Inc filed Critical Lipogenics Inc
Publication of EP1037628A1 publication Critical patent/EP1037628A1/en
Publication of EP1037628A4 publication Critical patent/EP1037628A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Prostheses (AREA)
EP98960259A 1997-11-17 1998-11-17 METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE Withdrawn EP1037628A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97170397A 1997-11-17 1997-11-17
US971703 1997-11-17
PCT/US1998/024606 WO1999025336A1 (en) 1997-11-17 1998-11-17 Methods for preventing restenosis using tocotrienols

Publications (2)

Publication Number Publication Date
EP1037628A1 EP1037628A1 (en) 2000-09-27
EP1037628A4 true EP1037628A4 (en) 2002-08-21

Family

ID=25518699

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98960259A Withdrawn EP1037628A4 (en) 1997-11-17 1998-11-17 METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE

Country Status (6)

Country Link
EP (1) EP1037628A4 (id)
JP (1) JP2001522880A (id)
AU (1) AU746369B2 (id)
CA (1) CA2310232A1 (id)
ID (1) ID26335A (id)
WO (1) WO1999025336A1 (id)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100730338B1 (ko) * 2000-03-31 2007-06-19 에자이 알앤드디 매니지먼트 가부시키가이샤 γ-토코트리에놀 함유 이뇨제
US7713546B1 (en) * 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
DK1521603T3 (da) 2002-07-12 2011-04-18 Cook Inc Coated medicinsk anordning
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
CN1897891A (zh) 2003-10-21 2007-01-17 医学技术设备公司 预防再狭窄的γ-生育酚疗法
US9592324B2 (en) 2006-11-06 2017-03-14 Atrium Medical Corporation Tissue separating device with reinforced support for anchoring mechanisms
US9801982B2 (en) 2004-09-28 2017-10-31 Atrium Medical Corporation Implantable barrier device
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
US20060067977A1 (en) 2004-09-28 2006-03-30 Atrium Medical Corporation Pre-dried drug delivery coating for use with a stent
EP1811935B1 (en) 2004-09-28 2016-03-30 Atrium Medical Corporation Heat cured gel and method of making
ES2619303T3 (es) 2005-06-01 2017-06-26 Edison Pharmaceuticals, Inc. Productos terapéuticos redox activos para el tratamiento de enfermedades mitocondriales y otras afecciones y modulación de biomarcadores energéticos
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
AU2006304590A1 (en) 2005-10-15 2007-04-26 Atrium Medical Corporation Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2007100652A2 (en) 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
US9492596B2 (en) 2006-11-06 2016-11-15 Atrium Medical Corporation Barrier layer with underlying medical device and one or more reinforcing support structures
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
MX363223B (es) 2008-09-10 2019-03-15 Bioelectron Tech Corp Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
EP2944332B1 (en) 2009-07-10 2016-08-17 Boston Scientific Scimed, Inc. Use of nanocrystals for a drug delivery balloon
EP2453938B1 (en) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucleation of drug delivery balloons to provide improved crystal size and density
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
NO2470168T3 (id) 2009-08-26 2018-06-30
US10322213B2 (en) 2010-07-16 2019-06-18 Atrium Medical Corporation Compositions and methods for altering the rate of hydrolysis of cured oil-based materials
EP2611476B1 (en) 2010-09-02 2016-08-10 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
WO2013028208A1 (en) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Medical device with crystalline drug coating
US9867880B2 (en) 2012-06-13 2018-01-16 Atrium Medical Corporation Cured oil-hydrogel biomaterial compositions for controlled drug delivery
RU2613167C2 (ru) * 2012-07-19 2017-03-15 Те Огайо Стейт Юниверсити Способ ослабления нарушения свертывания крови и связанные с этим материалы и методы
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4333794A1 (de) * 1993-10-04 1995-04-06 Carl Heinrich Dr Weischer Neue Acetyl-Salicylsäure-Derivate zur Bekämpfung von Entzündungs- und Schmerzzuständen sowie zur Thromboseprophylaxe und -terapie
EP0669132A1 (en) * 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591772A (en) * 1991-11-22 1997-01-07 Lipogenics, Inc. Tocotrienols and tocotrienol-like compounds and methods for their use
DE4333794A1 (de) * 1993-10-04 1995-04-06 Carl Heinrich Dr Weischer Neue Acetyl-Salicylsäure-Derivate zur Bekämpfung von Entzündungs- und Schmerzzuständen sowie zur Thromboseprophylaxe und -terapie
EP0669132A1 (en) * 1994-02-23 1995-08-30 van der Kraaij, Antonius Marinus Maria Pharmaceutical composition of vitamin E and acetylsalicylate for treatment and prevention of atherosclerosis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AZZI A ET AL: "MODULATION OF CELL PROLIFERATION BY TOCOPHEROLS AND TOCOTRIENOLS: ROLE IN ARTERIOSCLEROSIS", LIPID SOLUBLE ANTIOXIDANTS: BIOCHEMISTRY AND CLINICAL APPLICATIONS, BIRKHAEUSER VERLAG, BASEL, CH, 1992, pages 123 - 133, XP008004536 *
GELLER M R ET AL: "Palmvitee-induced carotid plaque regression in humans.", STROKE (26, NO. 1, 162, 1995) CODEN: SJCCA7 ISSN: 0039-2499, XP008004540 *
KARPEN C W ET AL: "TOCOTRIENOL-INDUCED INHIBITION OF PLATELET THROMBUS FORMATION AND PLATELET AGGREGATION IN A STENOSEL CORONARY ARTERY CANINE MODEL", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 4, PART 2, no. 90, 14 November 1994 (1994-11-14), pages 1181, XP008004384, ISSN: 0009-7322 *
KOOYENGA D ET AL: "ANTIOXIDANT EFFECTS OF TOCOTRIENOLS IN PATIENTS WITH CAROTID STENOSIS", JOURNAL OF INVESTIGATIVE MEDICINE, AMERICAN FEDERATION FOR CLINICAL RESEARCH,, US, vol. 3, no. 44, 3 May 1996 (1996-05-03), pages 245A, XP008004383, ISSN: 1081-5589 *
PACKER L: "INTERACTIONS AMONG ANTIOXIDANTS IN HEALTH AND DISEASE: VITAMIN E AND ITS REDOX CYCLE", PROCEEDINGS OF THE SOCIETY FOR EXPERIMENTAL BIOLOGY & MEDICINE, ACADEMIC PRESS INC. NEW YORK, US, vol. 2, no. 200, June 1992 (1992-06-01), pages 271 - 276, XP001073940, ISSN: 0037-9727 *
QURESHI A A ET AL: "NOVEL TOCOTRIENOLS OF RICE BRAN MODULATE CARDIOVASCULAR DISEASE RISK PARAMETERS OF HYPERCHOLESTEROLEMIC HUMANS", JOURNAL OF NUTRITIONAL BIOCHEMISTRY, BUTTERWORTH PUBLISHERS, STONEHAM, GB, vol. 8, no. 5, May 1997 (1997-05-01), pages 290 - 298, XP001026694, ISSN: 0955-2863 *
See also references of WO9925336A1 *
TOMEO A C ET AL: "ANTIOXIDANT EFFECTS OF PV IN HYPERLIPIDEMIC SUBJECTS WITH CAROTID ARTERY STENOSIS", CLINICAL RESEARCH, THOROFARE, NJ, US, vol. 2, no. 42, 29 April 1994 (1994-04-29), pages 158A, XP008004385, ISSN: 0009-9279 *
TOMEO ET AL.: "Antioxidant effects of vitamin E and gamma-tocotrienol in hyperlipidemic subjects with carotid artery stenosis - A preliminary report", CLIN. RES., vol. 42, no. 1, - 1994, pages 29a, XP008004386 *

Also Published As

Publication number Publication date
CA2310232A1 (en) 1999-05-27
WO1999025336A1 (en) 1999-05-27
JP2001522880A (ja) 2001-11-20
EP1037628A1 (en) 2000-09-27
AU746369B2 (en) 2002-04-18
AU1590299A (en) 1999-06-07
ID26335A (id) 2000-12-14

Similar Documents

Publication Publication Date Title
EP1037628A4 (en) METHOD FOR PREVENTING RESTENOSE USING TOCOTRIENOLE
EG24081A (en) 4-Substituted-9-deoxo-9a-aza-9a-homerythromycin derivatives
HUP0003642A3 (en) N-alkanoylphenylalanine derivatives
GB9702194D0 (en) Sulphonide derivatives
ZA987602B (en) N-alkanoylphenylalanine derivatives
PL334847A1 (en) Substituted 3-heterocyclyl-benzoyl derivatives
HU9801168D0 (en) Triazinylaminostilbene derivatives
HUP9802261A3 (en) Protector for cardans
GB2321457B (en) 5-Aroylnaphthalene derivatives
GB2322316B (en) Chuck
IL132982A0 (en) Cis-disubstituted aminocycloalkyl-pyrrolidine derivatives
PL340541A1 (en) Pyridipyrrole derivative
GB9715821D0 (en) Amidino-camptothecin derivatives
ZA9810039B (en) Azoline derivatives
GB9725541D0 (en) Amino-benzothiazole derivatives
GB9701628D0 (en) Imino-aza-anthracyclinone derivatives
ZA983116B (en) Arylsecocholadiene derivatives
AU6521198A (en) Agent for preventing restenosis
HU9800889D0 (en) New naphtylpiperazine derivatives
IL131159A0 (en) 4-Aminoethoxyindazole derivatives
GB9721196D0 (en) Pipeliner for renovation
GB2314014B (en) Closure-arrangements for loose-covers
GB9706753D0 (en) Aralkoxy-morphinan derivatives
SI1005445T1 (en) N-alkanoylphenylalanine derivatives
EG21550A (en) Catalys for hydroprocessing

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000616

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20020709

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030531